Glaxo May Face Generic Advair Sooner Than Expected

The FDA has issued a draft guidance that indicates the drugmaker may face generic competition for its best-selling Advair medication for asthma and chronic obstructive pulmonary disorder sooner than some thought. At issue is the ease with which generics may now win FDA approval based on bioequivalence and tap into a multi-billion-dollar market in just a few years.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news